Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

ut Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation; or Lori Williams of Baylor College ofMedicine, Office of Public Affairs
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/6/2009)..., SAN DIEGO, Nov. 6 California Ame... 2009 as "No Drugs Down the Drain" week for its Sa...campaign sponsored by public and private agencies ...ceutical pollution in our source water supplies. ,...customers are encouraged to drop off expired or un...
(Date:11/5/2009)..., EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ -...e emerging field of biologic products for regenera... the third quarter ended September 30, 2009. ,,...on the release of our three new biologic products ...chnology and Plexur M® Innovative Grafting," ...
(Date:11/5/2009)..., POINT RICHMOND, Calif., Nov. 5 /PRNewswire-First... TSPT ), a specialty pharmaceutical company focuse...rietary products that address important therapeuti...ced it will host a webcast and teleconference with...l results on Thursday, November 12, 2009, at 5:00 ...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 1NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 2Cost effectiveness of blood pressure device evaluated 59562 1Cost effectiveness of blood pressure device evaluated 59562 2Cost effectiveness of blood pressure device evaluated 59562 3Concordia University to construct new building for genomics research 10381 1Concordia University to construct new building for genomics research 10381 2Concordia University to construct new building for genomics research 10381 3Concordia University to construct new building for genomics research 10381 4Concordia University to construct new building for genomics research 10381 5Concordia University to construct new building for genomics research 10381 6
... KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - ...wed that a combination of,COPAXONE(R) (glatiramer ...minocycline reduced T1 Gadolinium (Gd)-enhancing l...ents with active,relapsing-remitting multiple scle...aging (MRI), compared to those receiving,COPAXONE(...
... Statistically Significant Improvements in Functio...t, RICHMOND, Calif., May 03, 2007 /PRNewswire-Firs...y the presentation of preclinical,data from its ZF...,the Fourteenth Annual Conference of the American ...nerated, in a model of spinal cord,injury (SCI), d...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 2Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 3Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 4
(Date:11/8/2009)...ewswire-USNewswire/ -- USAction this evening haile...a Act, which will make health care more affordable...le and increase access to health care for millions...y Roosevelt, FDR and Harry Truman would be proud,"...ay,s vote ranks among our country,s proudest achie...
(Date:11/8/2009)...sage of Health Care Reform Bill ,, Critical l...rage for all Americans ,, CHICAGO, Nov. 7 /PRN...use of Representatives passed by a vote of 220-215...ld strengthen Medicare for seniors and end discrim...s of Americans out of affordable health coverage. ...
(Date:11/7/2009)...ewswire-USNewswire/ -- Karen Ignagni, President an...released the following statement today on House pa...upport comprehensive health care reform, and we ha...omplete overhaul of how health insurance is provid...rage, elimination of pre-existing condition exclus...
(Date:11/7/2009)...CT), David A. Cook (GA), Louis J. Goodman (TX), Pa...,, CHICAGO, Nov. 7 T...ted five medical society executive leaders with ac...he goals and ideals of the medical profession. The...licy making meeting in Houston. ,, (Logo: ht...
(Date:11/7/2009)...olics have a responsibility to vigorously oppose a...o." ,, WASHINGTON, Nov. 7 /PRNewswire-USNew...own released the following statement on the news t...ncy Pelosi,s Affordable Health Care for America Ac...e status quo for abortion is voted upon. ,, "O...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2
...d the military doctors to reorient themselves to r...the rapidly changing global scenario in order to f...rces are the most potent form of delivering health...Conference here on Monday. Pointing out that t...
...de is high among the children of men who work unde...the University of British Columbia and several oth...oximately 30,000 men - who were working or had wor...yment, their physical work environment and their p...
...contribute to far reaching benefits, capable of av...to a US study, scientists have said that even a 15...terol that is amply found in the dairy products, m...University of Texas Southwestern Medical Center in...
...ive-day nationwide polio immunization campaign in ...d-one half million children, below the age of five...radication Campaign, David Heymann said, "In fact,...fficult part of the country logistically, it may b...
...lk. Prolacta Bioscience, a for-profit company, sta...n ounce. // Some mothers are also selling their ow...ut all this is going on with little regulation and...nter said that this might affect the people who ar...
...ulosis day. It was thought decades ago that the pr... it still remains a major // threat and its toll s...re still rising at almost 1% every year despite th... most recent World Health Organization data. This ...
Other Medicine News:Health News:Pranab Mukherjee Urged Military Doctors To Remain On The Cutting Edge 2Health News:Mama’s milk on sal 2Health News:Tuberculosis Is Still A Major Health Threat In Africa 2
Khosla Phaco System
Khosla Irrigation Aspiration Unit
...or Anterior and Posterior segment surgeries Vitrec... ECCE using Ventury or Peristaltic Linear Aspirati...for specific cutting action. Easy to read LED disp...-variable from 1- 600 cuts per minute. Independent...
Atraumatic Phaco Fixation Ring, 12mm Diameter
Medicine Products: